for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biomerica, Inc.

BMRA.OQ

Latest Trade

2.80USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.18

 - 

3.65

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.80
Open
--
Volume
--
3M AVG Volume
0.43
Today's High
--
Today's Low
--
52 Week High
3.65
52 Week Low
2.18
Shares Out (MIL)
9.89
Market Cap (MIL)
27.79
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Biomerica Inc Earnings Release

Latest Developments

More

Biomerica Announces Q2 Financial Results

Biomerica Signs Exclusive Distribution Agreement In China For Its Colorectal Screening Test

Biomerica Announces Third Quarter Sales Of $1.261 Million Versus $1.376 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biomerica, Inc.

Biomerica, Inc. is a biomedical company, which develops, manufactures and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The Company's medical diagnostic products are sold around the world in over two markets, including clinical laboratories and point of care (physicians' offices and over-the-counter drugstores). The Company operates in Europe, the United States, Asia, South America, the Middle East and other foreign countries. The Company's diagnostic test kits are used to analyze blood, urine or fecal specimens from patients in the diagnosis of various diseases and other medical complications, or to measure the level of specific hormones, antibodies, antigens or other substances, which exist in the human body in various concentrations. The Company primarily focuses on products for gastrointestinal (GI), food intolerances, diabetes and esoteric tests. The Company's diagnostic products use immunoassay technology.

Contact Info

17571 von Karman Ave

+1.949.6452111

http://www.biomerica.com/

Executive Leadership

Zackary S. Irani

Chairman of the Board, Chief Executive Officer

Janet Moore

Chief Financial Officer, Treasurer, Secretary, Director

Allen C. Barbieri

Independent Director

Francis R. Cano

Independent Director

Jane F. Emerson

Independent Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2018

-0.170

2019

-0.260

2020(E)

-0.240
Price To Earnings (TTM)
--
Price To Sales (TTM)
5.33
Price To Book (MRQ)
8.20
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-51.88
Return on Equity (TTM)
-39.39

Latest News

Latest News

BRIEF-Biomerica Q3 Sales $1.376 Million Versus $1.5 Million

* Q3 SALES $1.376 MILLION VERSUS $1.5 MILLION Source text for Eikon: Further company coverage:

BRIEF-Biomerica Says ‍Mexico's Cofepris' Approval Of EZ Detect Colorectal Screening Test​ - SEC Filing

* BIOMERICA SAYS MEXICO'S COFEPRIS' APPROVAL OF EZ DETECT COLORECTAL SCREENING TEST - SEC FILING

BRIEF-Biomerica Q2 Loss Per Share $0.03

* BIOMERICA ANNOUNCES SECOND QUARTER FINANCIAL RESULTS; SALES UP 12.7% FOR THE QUARTER

BUZZ-Biomerica: China's FDA approves colorectal screening test for cancer

** Diagnostic test maker's shares up as much as 64.77 pct to touch record high of $7.25 - biggest intraday pct gain since May 2016

BRIEF-China FDA Approves Biomerica Colorectal Screening Test To Help Identify The Early Warning Signs Of Colorectal Cancer

* CHINA FOOD AND DRUG ADMINISTRATION (CFDA) APPROVES BIOMERICA COLORECTAL SCREENING TEST TO HELP IDENTIFY THE EARLY WARNING SIGNS OF COLORECTAL CANCER Source text for Eikon: Further company coverage:

BRIEF-Biomerica Enters Into At Market Issuance Sales Agreement With B. Riley FBR

* BIOMERICA INC - ON DEC. 1, 2017, CO ENTERED INTO AN AT MARKET ISSUANCE SALES AGREEMENT WITH B. RILEY FBR, INC - SEC FILING

BRIEF-Biomerica extends license agreement with Celtis Pharm

* Biomerica extends exclusive license agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019

BRIEF-Biomerica Inc Q1 ‍net sales $1.4 million

* Net sales of $1.4 million for three months ending August 31, 2017, an increase of 2.4%

BRIEF-Biomerica commences clinical studies for new Gastroenterology H. Pylori test

* Biomerica commences clinical studies for new Gastroenterology H. Pylori test

BRIEF-Biomerica announces point of care product distribution agreement with a multinational pharmaceutical company

* Biomerica announces point of care product distribution agreement with a multinational pharmaceutical company

BRIEF-Biomerica files for stock shelf of up to $45 mln

* Biomerica Inc files for stock shelf of up to $45 million - SEC filing Source text: (http://bit.ly/2sqnkhi) Further company coverage:

BRIEF-Biomerica reports Q3 net loss of $304,141

* Biomerica announces third quarter financial results, sales up 13.9 pct for nine months

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up